You know how it is with the stock market—one day you’re up, the next day you’re questioning all your life choices. That’s where analysts like Vaishali Parekh come in. She’s been calling some pretty decent shots lately, and her latest picks—Network18, Nelco, and Zydus Lifesciences—are getting traders all excited. But are they actually good bets? Let’s break it down like we’re chatting at a Mumbai chai stall.
Okay, real talk—in the world of stock recommendations, everyone claims to be an expert. But Parekh? She’s the real deal. Been at Prabhudas Lilladher for ages, heads their research team, and here’s the thing: she doesn’t just throw darts at a board. Her calls are based on actual charts and patterns, not some gut feeling after eating bad vada pav. Traders swear by her because she tells you why a stock might move, not just that it will.
So here’s what she’s suggesting for June 2025. And no, this isn’t some “get rich quick” scheme—each has its pros and cons.
What They Do: Basically, if there’s news in India, Network18 is probably covering it. TV, websites—you name it. And business has been decent lately, with ads picking up again.
Why Parekh Likes It: She spotted this technical pattern called a “bullish flag”—sounds fancy, but it just means the stock could be gearing up for a run. With elections coming up? Ad money’s about to pour in. Could see 15-20% upside if things go right.
But Here’s the Catch: Government keeps changing media rules every other week, and let’s be honest—how many people actually watch TV news these days?
What They Do: Part of the Tata empire, these guys work on satellite tech and just landed a sweet ₹120 crore deal with the Navy.
Parekh’s Take: Stock finally broke past ₹750 after being stuck forever. That’s usually a good sign. Plus, defense spending is only going up—Modi government loves this sector.
Potential Headache: Ever dealt with government contracts? Delays happen. A lot. And if the Navy changes its mind, well…
What They Do: Medicines, mostly. Got approval recently for a diabetes drug in the US—big deal for a mid-sized company.
Why It’s Interesting: Big funds have been buying quietly, and the chart shows higher highs—that’s trader speak for “people are willing to pay more for it.” At 22 times earnings, it’s not crazy expensive compared to others.
What Could Go Wrong: American drug market is brutal—prices get cut overnight. One bad quarter and investors run for the exits.
Look, I’m no financial guru, but here’s how normal people should approach this:
Oh, and Zydus? Might be better to wait for a dip if you’re in it for the long haul.
Nifty’s been shaky around 23,500—everyone’s waiting to see what RBI does next. But here’s the interesting part: Parekh’s picks aren’t random. Media (elections), defense (government spending), pharma (safe sector). She’s playing specific trends, not just guessing.
That said, keep an eye on oil prices and the monsoon. In India, these two things mess with the market more than any analyst’s report.
Parekh’s picks make sense on paper, but here’s the truth—nothing’s guaranteed in the market. Network18 could soar if election ads boom, or get hammered if regulators step in. Nelco might ride the defense wave, or get stuck in paperwork. Zydus looks solid, but pharma stocks have burned people before.
My two cents? Do your homework, don’t bet the farm, and maybe put one of these on your watchlist. What do you think—any of these catch your eye?
Source: Livemint – Markets
Make fluffy, high-protein waffles with Greek yogurt! This easy recipe delivers moist, delicious waffles for…
Konami revives Metal Gear multiplayer with Fox Hunt in Delta: Snake Eater—nothing like Metal Gear…
Discover how Google Lens in Chrome can supercharge your workflow. Learn the best way to…
May wholesale prices increased 0.1%, under the expected 0.2%, signaling potential easing inflation pressures.
A recent Boeing 787 crash in India renews scrutiny over the plane maker's safety record…
Copilot Vision expands beyond Edge—now answers questions about any open file, app, or window on…